CA2303505A1 - A monoclonal antibody against estrogen stimulated leucine aminopeptidase - Google Patents

A monoclonal antibody against estrogen stimulated leucine aminopeptidase Download PDF

Info

Publication number
CA2303505A1
CA2303505A1 CA 2303505 CA2303505A CA2303505A1 CA 2303505 A1 CA2303505 A1 CA 2303505A1 CA 2303505 CA2303505 CA 2303505 CA 2303505 A CA2303505 A CA 2303505A CA 2303505 A1 CA2303505 A1 CA 2303505A1
Authority
CA
Canada
Prior art keywords
monoclonal antibody
antibody against
lapase
leucine aminopeptidase
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2303505
Other languages
French (fr)
Other versions
CA2303505C (en
Inventor
Gabriel Pulido-Cejudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canada Minister of Health
Original Assignee
Canada Minister of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002267481A external-priority patent/CA2267481A1/en
Application filed by Canada Minister of Health filed Critical Canada Minister of Health
Priority to CA 2303505 priority Critical patent/CA2303505C/en
Publication of CA2303505A1 publication Critical patent/CA2303505A1/en
Application granted granted Critical
Publication of CA2303505C publication Critical patent/CA2303505C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The identification and characterization of risk factors and their molecular implications in the pathophysiology of human diseases such as cancer is essential for designing efficient diagnostic assays and therapeutic compounds. Estrogenic steroids, under normal physiological conditions, have been shown to play a critical function in several tissues.
The response of such a variety of tissues to estrogen stimulation can explain in part its active role in the development and progression of different human diseases, particularly Breast Cancer. Searching for estrogen-responding cellular factors in parental cells of primary human breast carcinomas obtained from tumour biopsies an isoenzyme of putative Leucine Aminopeptidase (LAPase; EC 3.4.11.1) was idenditifed. Results have demonstrated that this marker is found to be elevated in the sera of women with invasive ductal and metastatic carcinomas. A monoclonal antibody against this cellular marker have been produced. This invention refers to the use of LAPase monoclonal antibodies for first line confimatory blood-based testing for Breast Cancer.
CA 2303505 1999-03-30 2000-03-30 A monoclonal antibody against estrogen stimulated leucine aminopeptidase Expired - Fee Related CA2303505C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2303505 CA2303505C (en) 1999-03-30 2000-03-30 A monoclonal antibody against estrogen stimulated leucine aminopeptidase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,267,481 1999-03-30
CA002267481A CA2267481A1 (en) 1999-03-30 1999-03-30 Critical interdependency: from the role of estrogen on breast cancer to the susceptibility of women towards hiv infection
CA 2303505 CA2303505C (en) 1999-03-30 2000-03-30 A monoclonal antibody against estrogen stimulated leucine aminopeptidase

Publications (2)

Publication Number Publication Date
CA2303505A1 true CA2303505A1 (en) 2000-09-11
CA2303505C CA2303505C (en) 2001-11-13

Family

ID=25680864

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2303505 Expired - Fee Related CA2303505C (en) 1999-03-30 2000-03-30 A monoclonal antibody against estrogen stimulated leucine aminopeptidase

Country Status (1)

Country Link
CA (1) CA2303505C (en)

Also Published As

Publication number Publication date
CA2303505C (en) 2001-11-13

Similar Documents

Publication Publication Date Title
BR0009483A (en) Monoclonal antibody against estrogen-stimulated leucine aminopeptidase
Malati Tumour markers: An overview
EP3026119B1 (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
Banfi et al. Behavior of tumor markers CA19. 9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer
WO2004065547A3 (en) Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
Cho et al. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S‐100 subunits
WO1998010069A3 (en) E25a protein, methods for production and use thereof
James et al. Salivary duct carcinoma secreting prostate-specific antigen
Rochaix et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen
Bose et al. Quantitative evaluation and correlation of serum glycoconjugates: Protein bound hexoses, sialic acid and fucose in leukoplakia, oral sub mucous fibrosis and oral cancer
US6235486B1 (en) Method for detection of breast cancer
EP3377903B1 (en) Use of circulating serum trop-2 as new tumor biomarker
Botta et al. Juvenile milk protein secreting carcinoma
Udagawa et al. Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT)
Rasbridge et al. Oestrogen and progesterone receptor expression in mammary fibromatosis.
CA2303505A1 (en) A monoclonal antibody against estrogen stimulated leucine aminopeptidase
Ben-Arie et al. Elevated serum alkaline phosphatase may enable early diagnosis of ovarian cancer
EP0753011B1 (en) Thymidine kinase tk1, peptide, corresponding antibodies and use of these in determination of tumor proliferation
Novaković Tumor markers in clinical oncology
CA2303598A1 (en) Tandem immuno-assay for cancer
Griffiths et al. The laboratory diagnosis of prostatic adenocarcinoma
Bogdanowicz et al. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia
Nasu et al. Serum levels of cytokeratin 19 fragments in cervical cancer
Mogensen et al. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours
Binder et al. High serum concentrations of relaxin correlate with dissemination of breast cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed